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(57) ABSTRACT 
Microcapsules prepared by encapsulating an aqueous solu- 
tion of a protein, drug or other bioactive substance inside a 
semi-permeable membrane by are disclosed. The microcap- 
sules are formed by interfacial coacervation under condi- 
tions where the shear forces are limited to 0-100 dyneslcm’ 
at the interface. By placing the microcapsules in a high 
osmotic dewatering solution, the protein solution is gradu- 
ally made saturated and then supersaturated, and the con- 
trolled nucleation and crystallization of the protein is 
achieved. The crystal-filled microcapsules prepared by this 
method can be conveniently harvested and stored while 
keeping the encapsulated crystals in essentially pristine 
condition due to the rugged, protective membrane. Because 
the membrane components themselves are x-ray transparent, 
large crystal-containing microcapsules can be individually 
selected, mounted in x-ray capillary tubes and subjected to 
high energy x-ray diffraction studies to determine the 3-D 
structure of the protein molecules. Certain embodiments of 
the microcapsules of the invention have composite poly- 
meric outer membranes which are somewhat elastic, water 
insoluble, permeable only to water, salts, and low molecular 
weight molecules and are structurally stable in fluid shear 
forces typically encountered in the human vascular system. 
8 Claims, 8 Drawing Sheets 
https://ntrs.nasa.gov/search.jsp?R=20080007450 2019-08-30T03:19:22+00:00Z
U S .  Patent Jan. 13,2004 Sheet 1 of 8 US 6,676,964 B2 
2- 
U S .  Patent Jan. 13,2004 Sheet 2 of 8 US 6,676,964 B2 
U S .  Patent Jan. 13,2004 Sheet 3 of 8 US 6,676,964 B2 
U S .  Patent Jan. 13,2004 Sheet 4 of 8 US 6,676,964 B2 
. 4  
U S .  Patent Jan. 13,2004 Sheet 5 of 8 US 6,676,964 B2 
U S .  Patent Jan. 13,2004 Sheet 6 of 8 US 6,676,964 B2 
U S .  Patent Jan. 13,2004 Sheet 7 of 8 US 6,676,964 B2 
U S .  Patent Jan. 13,2004 
csi z 
n 
E 
3 
a 
Y 
L 
w 
E m 
.I n 
Sheet 8 of 8 US 6,676,964 B2 
1 I 
1 I I 
0 cn 
0 
CD 
TI- 
LD 
03 
w 
cv 
d- 
CD 
m 
0 
m 
TI- cv 
co 
N 
F 
.r 
0 
US 6,676,964 B2 
1 
METHOD FOR DETERMINING THE 
PROTEIN 
THREE-DIMENSIONAL STRUCTURE OF A 
This application is a divisional of U.S. Patent Application 
No. 091079,766 filed May 15, 1998, now U.S. Pat. No. 
6,387,399, which is a continuation-in-part of U.S. Patent 
Application No. 081349,169 filed Dec. 2, 1994, now U.S. 
Pat. No. 5,827,531. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
The invention described herein was made in the perfor- 
mance of work under a NASA contract and is subject to 
Public Law 96-517(35 U.S.C. 5 200 et seq.). The contractor 
has not elected to retain title to the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention generally relates to methods of 
microencapsulating bioactive substances, and particularly to 
methods utilizing interfacial coacervation at the immiscible 
interface of two liquid phases. More particularly, the inven- 
tion pertains to such methods which maintain conditions of 
low shear force during formation of the microcapsules. The 
present invention also pertains to microcapsules formed by 
such methods and to their methods of use. 
2. Description of the Prior Art 
Liquid microcapsules and liposomes are often used to 
store and deliver bioactive substances such as drugs, 
enzymes or biocatalysts. One recent effort to provide lipo- 
somes with enhanced circulation times is that disclosed in 
U.S. Pat. No. 5,013,556 to Woodle et al. Liposomes created 
by Woodle et al. contain 1-20 mole % of an amphipathic 
lipid derivatized with a polyalkylether (such as phosphatidyl 
ethanolamine derivitized with polyethyleneglycol). Another 
improvement is provided by U.S. Pat. No. 5,225,212 (issued 
to Martin et al.) which discloses a liposome composition for 
extended release of a therapeutic compound into the blood- 
stream. Those liposomes are composed of vesicle-forming 
lipids derivatized with a hydrophilic polymer, wherein the 
liposome composition is used for extending the period of 
release of a therapeutic compound such as a polypeptide, 
injected within the body. Formulations of “stealth” lipo- 
somes have also been created with lipids that are less 
detectable by immune cells in an attempt to avoid phago- 
cytosis (Allen et al. (1992) Cancer Res. 52:2431-39.) Still 
other modifications of lipids (i.e., neutral glycolipids) may 
be made in order to produce anti-viral formulations. U.S. 
Pat. No. 5,192,551 to Willoughby et al. 1993. However, new 
types of liposomes and microcapsules are needed to exploit 
the various unique applications of this type of drug delivery. 
Many proteins of interest, such as those containing bio- 
active drug sites or enzymatically active sites, are only 
slightly soluble in aqueous solutions, which limits the quan- 
tity of drug that can be microencapsulated by usual tech- 
niques. In an effort to increase the amount of drug delivered 
to the target tissues, crystalline drug suspensions are some- 
times encapsulated. Fragile liposome or non-lipid carriers 
too often rupture or are pierced by the sharp crystals, 
however, leading to loss of the drug before it reaches its 
target. This undesired release of the drug crystals has also 
been known to damage the lining of blood vessels. 
Others have endeavored to increase the amount of drug in 
a liposome by loading the drug into the liposome by via a pH 
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gradient. U.S. Pat. No. 5,192,549 (issued to Barenolz and 
Haran) describes methods for forming liposomes and then 
obtaining transmembrane loading of amphiphatic drugs into 
the liposomes using an ammonium ion gradient between the 
internal and external aqueous phase on either side of the 
liposome membrane. The movement of ammonium from 
inside the liposome to the outside causes a pH change inside, 
thereby creating a driving force for the amphiphatic drug to 
be loaded or released through the membrane. Disadvantages 
of this method are that it requires the encapsulation of 
ammonium sulfate or another ammonium salt inside the 
liposomes, and transmembrane transport is limited to weak 
amphiphatic compounds. This type of drug concentrating 
method has not been used successfully to form encapsulated 
crystals, however. If this method were applied to protein 
crystal growth inside the liposome, it would be limited to 
applications where the protein was compatible with the 
ammonium salts and dissolved NH,. 
Another area where protein crystals are used is in mac- 
romolecular crystallography, which requires large, high- 
quality protein crystals. Conventional methods of growing 
protein crystals, as required for x-ray diffraction studies of 
three-dimensional structure, are often compromised by the 
formation of multiple small crystals, amorphous precipitates 
and aggregates rather than a single, or a few, large crystals 
from the limited amount of protein in the available mother 
liquor. It has been estimated that about 10’’ molecules are 
required to make up a crystal of sufficient size for x-ray 
crystallographic examination (Proteins Structures and 
Molecular Properties, 2nd Ed., Thomas E. Creighton, Ed., 
W. H. Freeman and Co., NY, N.Y., p. 203). It is often 
observed that, with conventional techniques, the best crys- 
tals begin to redissolve because of fluid perturbations at the 
crystal surface, temperature shifts and other changes in the 
mother liquor surrounding the crystal. Carrier fluids used to 
wash the crystal free from the mother liquor or used during 
mounting of the crystal (for x-ray diffraction) also tend to 
cause redissolution of the crystal before it can be analysed. 
There are many existing methods aimed at enhancing 
protein crystal growth, some of which take advantage of the 
favorable crystal growing conditions found in microgravity. 
An apparatus for carrying out crystallization of proteins and 
chemical syntheses by liquid-liquid diffusion in micrograv- 
ity is described in U.S. Pat. No. 4,909,933 (issued to Carter 
et al.) Another apparatus, disclosed in U.S. Pat. No. 5,130, 
105 (issued to Carter et al.) relies on vapor diffusion growth 
of protein crystals. Other recent microgravity-dependent 
methods are disclosed in U.S. Pat. No. 5,106,592 (issued to 
Stapelmann et al.), which deal with hanging drop vapor 
diffusion, dialysis of the protein solution, and interface 
diffusion between the protein solution and a precipitating 
agent. 
A ground-based (i.e., Earth normal gravity) method of 
concentrating protein solutions to obtain crystal growth is 
described by Todd et al. ((1990) J .  Crystal Growth 110: 
283-292), and U.S. Pat. No. 5,104,478 (issued to S. K. 
Sikdar et al.), which relies on osmotic dewatering of protein 
solutions. Todd et al. and Sikdar et al. describe the use of a 
dual chamber device wherein a near-saturated protein solu- 
tion is separated from a highly osmotic solution by a reverse 
osmosis membrane which allows dewatering, resulting in 
supersaturated conditions which in turn cause nucleation and 
protein crystal growth in the mother liquor. The main 
advantage of this method is that the rate of dewatering can 
be determined by the difference in osmotic pressure on either 
side of the membrane. One drawback of this method is that 
the nucleation and subsequent protein crystal growth 
depends on increasing the concentration of precipitant and 
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protein in the mother liquor. There is no control over the 
effects of solute driven convection on the surface of the 
crystal. As is the case with the protein crystals grown under 
conditions of microgravity, the crystals are not protected by 
any enclosure thus they are subject to physical damage as 
they are harvested and mounted. None of the existing 
methods for growing large, perfect crystals provide 
adequately protected protein crystals. 
In conventional x-ray diffraction studies to elucidate the 
three-dimensional structure of a protein, in order to avoid 
physical damage to protein crystals, the crystals have typi- 
cally been mounted in aqueous gels. There are problems, 
however, in removing the gel material without affecting the 
integrity of the protein crystal. It would be desirable if a 
protein crystal could be encapsulated in a shell or membrane 
that was able to protect the crystal from harsh environments 
which can cause degradation. A crystal contained within a 
closed, non-degrading environment would be useful to those 
working in fields requiring high quality, intact protein crys- 
tals. Also needed is a way to grow larger and better quality 
protein crystals by eliminating some of the physical factors 
which perturb crystal growth and by better controlling the 
dewatering conditions to promote single crystal growth. It 
would be desirable to have a method of preparing protein 
crystals entrapped in liquid filled microcapsules surrounded 
by a thin, flexible outer membrane, yet are sturdy enough to 
protect the enclosed crystals from conditions which might 
cause fracture or fluid convection that can alter the molecu- 
lar arrangement at the crystal surface, or dissolution. 
Also needed are better carriers for drugs, particularly 
crystalline drugs, which can resist prematurely rupturing and 
can provide sustained and/or controlled release at a thera- 
peutic target site, and protect tissues from the sharp edges of 
the crystals. 
SUMMARY OF THE INVENTION 
Accordingly, it is an object of the present invention to 
provide microcapsules containing solutions and/or crystals 
of bioactive substances such as drugs and proteins, that have 
semi-permeable membranes which are rugged enough to 
protect fragile crystals and to resist shear and other mechani- 
cal forces typically associated with handling of such crys- 
tals. 
It is another object of the present invention to provide 
microcapsules containing highly ordered structures of other 
bioactive agents, or biomolecules, such as DNA, RNA or 
oligonucleotides, which are capable of being transported 
intact through the human vascular system for release at a 
desired site of action. 
It is another object of the invention to provide microcap- 
sules having outer “skins” or membranes which avoid being 
readily detected and eliminated by the reticuloendothelial 
system, and which protect the microcapsules against shear 
forces encountered during use, particularly during transport 
within the vascular system en route to target tissues. 
Another object is to optimize the concentration of a 
bioactive agent in a microcapsule in order to achieve sub- 
sequent sustained or controlled release of the agent. 
It is a further object of the invention to provide micro- 
capsules which provide a closed environment that is favor- 
able for growth of crystals under prescribed conditions of 
dewatering. 
Still another object of the invention disclosed herein is to 
provide a method for making custom microcapsules con- 
taining protein crystals of suitable quality for X-ray diffrac- 
tion studies of native and activated protein structures. 
4 
A further object of the invention to provide larger micro- 
capsular packages containing saturated or near-saturated 
solutions of these bioactive substances than has been pos- 
sible before, and to provide an environment for these micro- 
5 capsules that is conducive to growing large crystals inside 
the microcapsule, or to accommodate larger 3-D ordered 
structures than has previously been possible. 
By entrapping protein crystals in these special purpose 
microcapsules, they can be protected from conditions which 
10 might cause fracture of the crystals or fluid convection 
which can alter the molecular arrangement at the crystal 
surface, or dissolution. The semi-permeable membrane pro- 
vided by the invention not only protects the crystals from 
harsh environments which can cause degradation, it also 
1s provides a closed environment which favors crystal growth 
under prescribed conditions of controlled dewatering. 
In addition to crystallizable proteins or drug that are 
chemical compounds, many other bioactive substances 
which are capable of forming a highly ordered structure may 
20 be similarly microencapsulated. For instance, a duplex DNA 
strand or RNA-like structure, or a concentrated solution of 
an oligonucleotide or a polyribo- or -deoxyribonucleotide or 
other labile biological are also suitable for entrapment 
according to the methods of the present invention. 
zs Accordingly, the present invention provides a basic method 
of making a microcapsule comprising preparing a first phase 
containing a first solvent, a co-solvent and a first polymer 
dissolved therein. The method includes preparing a second 
phase of different density than the first phase, the second 
30 phase also including a second solvent, a surfactant, a salt, 
and a bioactive substance, all dissolved in the second phase. 
In this method the first polymer and surfactant are selected 
such that the hydrophobicilipophilic balance value (HLB) of 
the surfactant is greater than the HLB of the first polymer. 
35 Thusly made, the first and second phases are capable of 
forming a mutual interface. 
The basic method of making a microcapsule that contains 
a protein or bioactive agent preferably also has a second 
polymer dissolved in the second phase. In this case, the first 
40 polymer, second polymer and surfactant are each selected 
such that their respective hydrophobicilipophilic balance 
values (HLB) are in the following order: surfactanbsecond 
polymer>first polymer. Upon bringing the two phases 
together gently, to form an interface, and by limiting fluid 
45 shear forces at the interface to about e 5 0  dynesicm’, 
microcapsules containing the dissolved bioactive agent are 
formed. Preferably the shear forces are limited to about 
0-100 dynesicm’ so as to form larger microcapsules. 
In preferred embodiments of the invention, the bioactive 
SO substance is a protein which is dissolved in the second phase 
at a concentration that is at or near saturation. In some 
embodiments, a crystal of the protein is also suspended in 
the second phase solution. If the protein is particularly 
susceptible to degradation, a protein stabilizing agent may 
The first solvent is preferably water, methanol, ethanol, 
isopropanol, n-hexanol, or n-heptanol, or a hydrocarbon 
having a low or medium HLB 5-10. The co-solvent is 
preferably a 3-carbon to 8-carbon (C,-C,) normal alcohol, 
60 tetrahydrofuran, dioxane, acetonitrile, dimethylformamide, 
dimethylacetamide, dimethylsulfoxide or a similar solvent. 
The first polymer is preferably a polymer of glycerol 
monostearate, glycerol monooleate, glycerol monolaurate, 
glycerol dioleate, glycerol distearate or other hydrophobic 
65 mono- or polyglycerides or waxy polymers of low molecular 
weight, or it can be a combination of any of those polymers. 
ss be included in the second phase solution. 
In an alternative method of the invention, however, the first 
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solvent is water and the first polymer is a polyethylene the second phase having a different density than that of the 
glycol having a molecular weight greater than about 400 kd, first phase. The second phase is water containing polyeth- 
cyclodextrin, polyvinylpyrrolidine or polyvinyl alcohol. In ylene glycol, as a surfactant, and a second polymer dissolved 
another alternative embodiment, an alternative membrane therein. This second Polymer, which is capable of adhering 
forming material comprising a sterol or a phospholipid is s to the first Polymer, is PEG 1NK-8000. A Protein is also 
substituted for the first polymer, The sterol or phospho~ipid dissolved to saturation or near-saturation in the second 
may be cholesterol, stigmasterol, phytosterol, campesterol, phase. optionally, One Or more crysta1s may be sus- 
pended in the second phase solution. The second phase also phosphatydyl choline or CENTROLEX-FTM. 
In preferred methods of making the microcapsules of the includes NaCl dissolved therein. An important feature of this 
method is that the first polymer, second polymer and sur- present invention, the second solvent is water and the i o  factant are chosen such that the hydrophobicilipophilic 
Of about 10-40. The HLB Of the first polymer is preferably polymer. When the two phases are gently brought into direct 
less than the HLB Of the surfactant by Or more HLB units. contact, an interface forms between them. It is a critical part 
sorbitan monooleate plus ethylene oxide, dextran, p o k t h -  15 limited to 0-100 dynes/cm2 so that microcapsules having the 
Ylene glycol (PEG), Ciz-czo fatty acids, and quaternary desired characteristics will form. After microcapsules have 
NH, salts. formed, the outer membrane is then cured to make it more 
The second polymer is preferably capable of adhering to rugged and durable. Optionally, an additional polymer coat- 
the first polymer and is chosen from the group consisting of ing may be applied over the outer membrane if an even 
PEG 400-20000, dextran 400&20,000, a polysaccharide of 20 thicker membrane, or skin, is desired. 
mol. wt. ranging from about 10,000-100,000, polyvinylpyr- Also provided in accordance with the present invention is 
rolidone (PVP), a polyvinyl alcohol and other similar poly- an improved method of determining the three-dimensional 
meric materials. structure of a predetermined protein molecule by x-ray 
In preferred embodiments the salt contained in the second crystallography. The improvement includes forming a 
phase solution is NaC1, KC1, CaCl,, quaternary NH, salts, zs microcapsule containing a saturated or near saturated aque- 
cetyl trimethylammonium bromide, 2-amino-2-methyl ami- ous solution of a protein surrounded by a semi-permeable 
nomethyl propanol or a similar salt. polymeric membrane. The microcapsule is exposed to a 
According to the preferred methods of the invention, after dewatering solution having a higher osmotic pressure than 
initial formation of the microcapsule, the membrane is the encapsulated protein solution, whereby water is osmoti- 
allowed to cure. After curing, the relatively sturdy micro- 30 cally removed from said encapsulated protein solution. By 
capsules may be separated into fractions of a certain size controlling the concentration of a dewatering agent in the 
range, if desired for a particular purpose, such as injection dewatering solution, gradual, ordered crystallization of the 
into a blood vessel for therapeutic treatment. After curing, protein occurs within the microcapsule. This gradual, 
the microcapsules may then be subjected to gradual dewa- ordered crystal growth is allowed to continue until the 
tering in order to gently bring about supersaturation of the 35 crystal becomes at least about 50-300 microns across one 
bioactive agent and to encourage single crystal nucleation face. A microcapsule containing a crystal of sufficient size 
and growth. Optionally, an additional coating of polymer and crystalline quality is then carefully selected. The micro- 
may be applied to the microcapsule, after curing, after capsule is mounted in an x-ray capillary tube and subjected 
dewatering, or after full growth of the crystal has been to a high energy x-ray crystallographic procedure to obtain 
accomplished, in order to provide a thicker, more protective 40 a characteristic x-ray diffraction pattern of the protein crys- 
surfactant has a hydrophilicflipophilic (HLB) balance values (HLB) are: surfactant>second polymer>first 
The surfactant may be chosen from the group Of of this method that the fluid shear stress at the interface be 
skin on the microcapsule. 
The dewatering step of certain embodiments of the inven- 
tion may include exposing the microcapsule to a closed local 
environment which is capable of regulating the rate and 
extent of microcapsule dewatering whereby controlled crys- 
tallization of a protein occurs within said microcapsule. The 
dewatering step may include exposing microcapsules to a 
dewatering solution containing a salt or a polymer which is 
excluded by the semi-permeable membrane of the micro- 
caasule. In an alternative embodiment. the method includes 
tal. 
In an alternative and preferred method of performing 
x-ray crystallography on a crystal specimen, the present 
invention provides an improvement over methods which 
45 include isolating a crystal specimen in a fiber loop with an 
attached handle portion, freezing the crystal specimen, 
mounting the crystal specimen and fiber loop on a goniom- 
eter head such that said crystal is positioned in a continuous 
N, stream loop, and rotating the goniometer head in an x-ray 
SO beam. The aresent imarovement includes substituting for the v 
diffusing a low molecular weight salt into said interior cavity conventional crystal specimen a microencapsulated crystal 
to induce single crystal nucleation and crystal growth. that has a protective outer membrane surrounding a large 
In certain embodiments employing a closed local envi- crystal and a small amount of mother liquor. The membrane, 
ronment for dewatering the microcapsule, the environment which is preferably a composite of two or more polymers, is 
may also permit controlling the protein concentration and ss substantially transparent to the x-ray beam so that it does not 
the concentration of charged precipitant molecules at or near interfere with the x-ray diffraction pattern of the crystal. 
the surface of a growing protein crystal so that the internal According to this improved method, the membrane has an 
order and extent of crystallization of said protein crystal is electrostatic charge which renders the microencapsulated 
optimized. crystal electrostatically attracted to the fiber loop. This 
One preferred method of making a microcapsule includes 60 electrostatic attraction is strong enough to support the 
preparing a first phase containing a first solvent chosen from microencapsulated crystal inside said loop. Optionally, a 
the group consisting of  methanol, ethanol, isopropanol, drop of liquid may be adhered to the outer membrane of the 
m-hexanol, or n-heptanol, a co-solvent chosen from the microencapsulated crystal to facilitate freezing. In certain 
group consisting o f  a 3-carbon to 8-carbon (C,-C,) normal embodiments the membrane is negatively charged and the 
alcohol, and a first polymer dissolved in the first phase. The 65 loop is a fiber having a positive electrostatic charge. In 
first polymer is a hydrophobic mono- or polyglyceride. certain preferred embodiments the crystal is a highly ordered 
According to this method, a second phase is also prepared, protein crystal. 
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The present invention also provides a microencapsulated 
protein crystal prepared by certain methods described above. 
In some embodiments the microcapsule is best characterized 
as a product of a particular method of the invention, because 
the inventors believe that there are as vet unrealized features 
and characteristics of the new microcapsules which are 
attributable to the novel method of making. 
In accordance with the present invention, a microcapsule 
is provided having an outer membrane surrounding an 
interior cavity, the interior cavity containing a saturated or 
nearly saturated solution of a bioactive agent. An important 
feature of this new microcapsule is that it is capable of 
withstanding shear forces at least as great as the turbulent 
blood flow within a human artery. 
Certain embodiments of the new microcapsule have a 
membrane containing at least one of the membrane forming 
material materials described above in the summary of the 
methods, descriptions. In the preferred embodiments, the 
membrane is a composite containing a first polymer and a 
second polymer that is capable of adhering to the first 
polymer. The HLB of the second polymer is preferably 
greater than the HLB of the first polymer. 
In certain embodiments of the microcapsule of the present 
invention, the interior cavity also contains the protein or 
bioactive agent in the form of a highly ordered structure such 
as a crystal. In some embodiments the crystal substantially 
fills the interior cavity. The membrane may even substan- 
tially conform to the shape of a large crystal. In preferred 
embodiments, the membrane is resistant to rupturing or 
piercing by the crystal. 
In certain embodiments the microcapsule’s membrane is 
permeable to water and low molecular weight salts but 
impermeable, or only slightly permeable, to the bioactive 
agent. In some embodiments, the membrane is less than or 
equal to 1 micron in thickness, and in others the membrane 
is about 3-5 microns thick. 
Preferably the bioactive agent is a protein or a drug, 
however in some embodiments of the microcapsule of the 
invention the bioactive agent is a biomolecule such as a 
polypeptide, oligonucleotide, RNA, DNA or other com- 
pound which can be crystallized. 
Certain embodiments of the new microcapsule include a 
highly ordered structure, such as a crystal, about 50-2000 
microns in size. 
Certain alternative embodiments of the microcapsule of 
the invention have an interior cavity that contains a hydro- 
phobic phase surrounded by and partially immiscible with a 
saturated or near-saturated solution of the bioactive agent. 
Also provided by the present invention is a composition 
comprising a multiplicity of certain microcapsule of the 
invention suspended in an aqueous solution having higher 
osmotic pressure than that of the bioactive agent solution. 
The higher osmotic aqueous solution may include a dewa- 
tering agent capable of causing water to be transported 
through said membrane and out of said interior cavity. This 
dewatering agent may be a salt or a high molecular weight 
polymer which is excluded by said membrane. 
Certain embodiments of the new microcapsules have a 
polymeric membrane that is transparent to x-ray radiation 
and/or does not interfere with the x-ray diffraction pattern of 
the highly ordered structure. 
The present invention accordingly provides an x-ray 
crystallography reagent for use in elucidating the three- 
dimensional structure of a predetermined biomolecule 
which is capable of forming a highly ordered structure. The 
reagent comprises a dewatered microcapsule prepared 
according to certain methods of the invention and having a 
8 
highly ordered structure, such as a protein crystal, substan- 
tially filling the interior cavity of the microcapsule. 
The present invention also provides a pharmaceutical 
composition comprising a pharmacologically effective mul- 
5 tiplicity of certain microcapsules of the invention, together 
with a pharmacologically acceptable carrier. For particular 
medical uses, the average size of the microcapsules is about 
1-20 microns, and for others the average size of said 
microcapsules is about 5&300 microns, or even greater than 
about 300 microns. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1A is a conceptual diagram of the procedure for 
forming a microcapsule of the present invention and for 
obtaining crystal growth within the microcapsule and 
15 mounting the encapsulated crystal for x-ray diffraction 
analysis. 
FIG. 1B shows conceptually a composite polymeric skin 
on certain microcapsules of the present invention. 
FIG. 1C shows an alternative embodiment of the micro- 
20 capsules of the invention as used for x-ray crystallography. 
FIG. 2 is a photomicrograph of lysozyme crystals grown 
inside a microcapsule, formed under microgravity 
conditions, and having a hydrophobic, semi-permeable 
polymeric outer membrane in accordance with the present 
FIG. 3 show concanavalin A inside microcapsules of the 
present invention. 
FIG. 3A is a photomicrograph showing concanavalin A 
crystals and solution contained in a microcapsule of the 
FIG. 3B is a photomicrograph showing concanavalin A 
crystals and solution contained in a microcapsule of the 
present invention formed in microgravity conditions aboard 
the Space Shuttle (magnification=150x). 
FIG. 4 is a photomicrograph of amoxicillin crystals inside 
a microcapsule of the present invention formed at 1 g. 
FIG. 5 is a photomicrograph of a preformed lysozyme 
crystal that was subsequently microencapsulated (1 g) and 
4o dewatered according to a method of the present invention, 
and then submersed in water (magnification=lOOx). 
FIG. 6 shows cis-platin crystals inside microcapsules of 
the present invention. 
FIG. 6Ais a photomicrograph of a single cis-platin crystal 
FIG. 6B is similar to FIG. 6A and shows the additional oil 
layer. 
FIG. 6C is similar to FIG. 6A but includes superimposed 
fitted lines for measurement of crystal size. 
FIG. 7 is a conceptual drawing of an alternative embodi- 
ment of a microcapsule of the present invention, having a 
membrane surrounding an aqueous solution containing a 
bioactive material which itself surrounds a partially immis- 
cible hydrocarbon core. 
FIG. SA is a graph showing the distribution of sizes of 
microcapsules containing photofrin produced by a represen- 
tative method of the present invention under low shear Earth 
normal gravity conditions. 
FIG. SB is a graph showing the distribution of sizes of 
6o microcapsules containing photofrin produced by a represen- 
tative method of the present invention under low shear 
microgravity conditions. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Microgravity research has provided a new understanding 
of mechanisms of fluid mechanics, interfacial behavior, and 
10 
25 invention (magnification=400x). 
30 present invention formed at 1 g (magnification=150x). 
35 
45 inside a microcapsule of the present invention containing; 
50 
55 
65 
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many biological processing methods that are compromised 
by gravity-dependent phenomena. As demonstrated by the 
inventors in U.S. patent application Ser. No. 081349,169 
(now U.S. Pat. No. 5,827,531), liquid microcapsules having 
two or more concentric layers can be made in a single step 
by slowly bringing two immiscible liquid phases (of differ- 
ing densities) together under conditions where the surface 
tension and diffusive forces are greater than the convective 
forces. The mechanisms of spontaneous formation of large 
microcapsules in microgravity have been further investi- 
gated by the inventors to develop new methods to make 
these and other unique microcapsules in both Earth-based 
and in microgravity environments. The disclosure of U.S. 
patent application Ser. No. 081349,169 (now U.S. Pat. No. 
5,827,531) is incorporated herein by reference. 
There are no prior art methods wherein protein crystals 
are encapsulated in a semi-permeable membrane which 
protects the crystals from harsh environments which can 
cause degradation. For the purposes of the present 
disclosure, the term “semi-permeable membrane” includes 
the usual definition and, when the context allows, also 
means that water and low-molecular weight salts can pass 
through the membrane, but the membrane is impermeable to 
a protein or other bioactive agent contained by the micro- 
capsule of the present invention. 
Neither are there any prior art methods that provide a 
closed environment that favors crystal growth under pre- 
scribed conditions of controlled dewatering within a micro- 
capsule or inside a polymer membrane. Known methods 
utilizing osmotic dewatering for growing protein crystals 
has relied on use of small chambers having a planar reverse 
osmosis membrane positioned between the mother liquor 
and the dewatering (high osmotic pressure) salt solution. 
The present method uses spherical microcapsules wherein 
the entire outer membrane surface is available for osmotic 
dewatering, also for infiltration by hydrogen or hydroxyl 
ions thereby changing the pH within the microcapsule to 
favor or enhance protein saturation and subsequent crystal 
growth. The membrane also can allow diffusion of salt ions 
into the microcapsule to decrease the solubility of the 
protein or bioactive agent. The increased surface area of the 
spherical microcapsule allows for more rapid change in 
conditions throughout the sphere of mother liquor, hence 
faster controlled changes all around the crystals which 
enhances the formation of more ordered and perfectly 
formed crystals. 
EXAMPLE 1 
General Procedure for Microcapsule Preparation 
Gravity-dependent restrictions in the basic liquid-liquid 
spontaneous microencapsulation process led to the design of 
several microgravity experiments to explore the utility of 
this process when density-driven phenomena were elimi- 
nated. In particular, density-driven, gravity-dependent 
restrictions of the liquid-liquid microencapsulation process 
were: early phase separation producing fragile microcap- 
sules; and interfacial dynamic flow causing coalescence of 
microcapsules. Failure of early ground-based experiments to 
derive uniform microcapsules lead to a desire to attempt 
microcapsule formation in space. 
The microgravity flight experiments led to the develop- 
ment of a liquid-liquid microencapsulation process that 
involves use of surfactants and co-surfactants in the aqueous 
phase and co-solvent/co-surfactant alcohols in the organic 
phase, which also contained high molecular weight poly- 
S 
10 
1s 
20 
2s 
30 
3s 
40 
4s 
so 
5s 
60 
65 
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mers that formed a tough, yet flexible, outer “skin” on the 
final microcapsules. The inventors’ earlier work in micro- 
gravity conditions included a single step dispersion which 
produced unique multi-lamellar microcapsules containing 
various aqueous drugs co-encapsulated with iodinated 
poppy seed oil (a radiocontrast medium with a sp. gravity= 
1.35). Subsequent ground control experiments also pro- 
duced some of these unique microcapsules and illustrated 
that the Earth normal (1 g) process could be improved to 
yield useable microcapsules by varying the liquid phase 
formulations. 
In further studies, it has become clear that the flexible 
outer skins, or membranes substantially improve the rug- 
gedness of the microcapsules formed. The inventors have 
gone on to develop a method of forming microcapsules that 
have a low molecular weight, water permeable outer “skin” 
or membrane surrounding a sphere of aqueous mother liquor 
containing a dissolved protein. The method utilizes a 
protein-impermeable polymer dissolved in a liquid organic 
phase. Formation of the microcapsule occurs by interfacial 
coacervation at the immiscible interface of the organic and 
aqueous phases, trapping the protein “mother liquor” inside. 
The general procedure for forming microcapsules is 
essentially as disclosed by the inventors in U.S. Pat. No. 
5,827,531, and as described below. The disclosure of that 
application is incorporated herein by reference, to the extent 
that it provides details supplementary to those set forth 
herein. 
The method of the present invention relies on liquid- 
liquid interactions. In the basic method, the first step entails 
formulating a first phase or layer (“Phase 1”) while the 
second step entails formulating a second phase or layer 
(“Phase 2”). The two phases are formulated to be substan- 
tially immiscible with one another. For the purposes of this 
invention, “immiscible” means that the two adjoining phases 
or layers have sufficiently different densities, viscosities or 
surface tensions to permit the formation of a mutual inter- 
face resembling a meniscus, or visible interface. 
As shown in Table 2 and the details that follow, formu- 
lating Phase 1 comprises combining a first solvent (which is 
preferably hydrocarbon based), a first polymer soluble in the 
first phase and a co-solvent. The first polymer is selected to 
be one which is soluble in the first phase and when formed 
into the microcapsule membrane is permeable to aqueous 
solvents and ions but impermeable to proteins or peptides. A 
small amount of a co-solvent is also added to the first phase, 
which co-solvent may also function as a co-surfactant. 
The method next calls for formulating a second phase 
(“Phase 2”), which is preferably aqueous and is immiscible 
with the first phase. The second phase comprises a second 
solvent, a second polymer soluble in the second phase but 
insoluble in the first phase, a surface active agent 
(“surfactant”), a dissolved salt and a dissolved protein or 
other bioactive substance of interest. The bioactive sub- 
stance may also be in the form preformed crystals suspended 
in a concentrated solution of the same bioactive substance. 
In order to ensure that the liquid-liquid interactions nec- 
essary to form the microcapsule will occur, certain of the 
constituents of Phases 1 and 2 are selected relative to one 
another (i.e., based on certain characteristics of one 
component, the second is selected advantageously based on 
its respective characteristics. After selecting the immiscible 
organic and aqueous solvents, the surface active agent in the 
second phase is selected such that it will have a hydrophilic/ 
lipophilic balance (“HLB”) value greater than that of the 
first polymer constituent of the first phase (Polymer 1). 
US 6,676,964 B2 
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Generally, the most useful surface active agents are those 
which are nonionic and which have a hydrophilicllipophilic 
balance value of 10.0 or greater. Next, the second polymer 
constituent of the second phase (Polymer 2) is selected to 
have a hydrophilicllipophilic balance value lower than that 
of the surface active agent constituent of the same phase. 
While not an exhaustive list, certain hydrophilicllipophilic 
balance values of materials which may be used in the 
formulations of the invention as Polymer 1 or Polymer 2 are 
provided in Table 1 below. See McCutcheon’s Detergents 
and Emulsifiers (1979) North American Edition, McCutch- 
eon Division, MC Publishing Co., 175 Rock Road, Glen 
Rock, N.J. 07452, for specific HLB values ranging from 2 to 
42, see pages 23-39; and for HLB values ranging from 0.5 
to 30.5, see pages 228-241. In making suitable polymer 
selections, it is important that the first polymer have an HLB 
value less than that of the surface active agent which, in turn, 
has an HLB value which is greater than that of the second 
polymer. 
TABLE 1 
HYDROPHILICiLIPOPHILIC BALANCE JHLB) (McCutcheon 19791 
Compound HLB 
Glycerol treioleate 
Cholesterol 
Triglyceride of coconut oil 
Sorbitan trioleate 
Sorbitan tristearate 
Glycerol monooleate 
Mono and di glycerides of fat-burning fatty acids 
Glycerol Monostearate (gms) 
Propoxylated ethylene diamine plus 
ethylene oxide 
Monoidiglyceride 
Glycerol mono coconut 
Monoidiglyceride 
Propylene glycol mono fatty acid ester 
Monoethoxyl lauryl ether 
Stearyl lactyl acid 
Hydrogenated cottonseed oil 
Sodium lauryl sulfate 
Mono and diglycerides with citric acid or 
lactylic ester or fatty acid 
Ethoxylated fatty amine (2 moles ETO) 
Diethylene glycol monostearate 
Sorbitan monopalmitate 
Diethylene glycol monostearate and oleate 
Ethoxylated (2) cetyl ether 
Glycerol Monoricinoleate 
Glycerol monolaurate 
Triglycerol mono stearate 
Polyethylene glycol (400 dioleate) 
Lanolin sterol 
Ethoxylated nonyl phenol (CO-420 & CO 850) 
Polyethylene glycol (400) distearate 
Sorbitan monolaurate 
Ethoxylated sorbitan fatty acid esters 
and alkyliaryl alcohol 
Anhydrous lanolin 
Polyethylene glycol monostearate 
Polyethylene glycol 400 
Ethoxylated (10) cetyl ether 
Ethoxylated glycerol monostearate (GMS) 
Sorbitan monostearate 
Sorbitan monooleate with 20 moles ethylene 
oxide 
Ethoxylated (20) oleyl ether 
Ethoxylated (20) stearyl cetyl ether 
Ethoxylated castor oil 
Nonyl phenol polyethylene glycol ether 
Polyethylene glycol 600 mono laurate 
Sodium lauryl sulfate 
Propylene glycol monostearate 
Hydroxylated lanolin sodium oleyl sulfate 
0.8 
1.0 
1.4 
1.8 
2.1 
2.7 
2.8 
2.8-5.0 (3.8 preferred) 
3-28 
3.2 
3.4 
3.5 
3.5 
3.6 
3.8 
3.8 
4.0 
4.24.6 
4.5 
4.7 
4.7 
4.7 
5.3 
6.4 
6.8 
7.0 
7.2 
8.0 
8.0-16.0 
8.2 
8.6 
9.0 
10.0 
11.0 
11.2 
12.9 
13.1 
14.9 
15.0 
15.3 
15.8 
18.0 
18.1 
19.6 
40 
40 
42 
12 
TABLE 1-continued 
HYDROPHILICiLIPOPHILIC BALANCE JHLB) (McCutcheon 1979) 
Compound HLB 
Blends of GMS and sorbitan monooleate 
with 20 mols ethylene oxide 
52 
10 
TABLE 2 
General Formulations for the Two Phases 
Phase 1 Phase 2 
75-90% (vi.) Solvent 1 70-98% (vi.) Water 
15 
0-20% (vi.) Co-solvent 1-4% (wiv) Surfactant 
1-5% (wiv) Polymer 1 1-10% (wiv) Polymer 2 
1-3% (wiv) Salt 
1% to saturation Bioactive Substance 
20 
Solvent 1 
Solvent 1 is preferably ethanol, methanol, isopropanol, 
n-hexanol, or n-heptanol, or another hydrocarbon having a 
low or medium HLB of 5-10. As a less preferred alternative, 
25 water may be substituted for the hydrocarbon if, for 
example, it is desirable to avoid the use of a hydrocarbon. 
Co-Solvent 
The Co-solvent is a 3-carbon to 8-carbon (C,-C,) normal 
a lcohol ,  te t rahydrofuran,  d ioxane ,  acetoni t r i le ,  
30 dimethylformamide, dimethylacetamide, dimethylsulfoxide 
or the like. An acceptable co-solvent also acts as a surfactant 
and preferably has a high dielectric constant, i.e. in the range 
of about 10-20. 
Polymer 1 
Suitable outer skin forming compounds which can be 
used as Polymer 1 are: glycerol monostearate, glycerol 
monooleate, glycerol monolaurate, glycerol dioleate, glyc- 
erol distearate, or other hydrophobic mono- or polyglycer- 
ides or waxy polymers of low molecular weight, or a 
40 combination of the foregoing polymers, which are capable 
of forming a thin, semi-permeable membrane. 
Alternatively, a hydrophobic aqueous phase may be sub- 
stituted for the Phase 1 liquid, if desired, as mentioned above 
with respect to Solvent 1. In this alternative water is used as 
45 the primary solvent and a polymer such as a high molecular 
weight polyethylene glycol (mol. wt. greater than 400 kd), 
cyclodextrin, polyvinylpyrrolidine or polyvinyl alcohol is 
dissolved therein. The particular polymer selected should be 
insoluble in the second aqueous phase (Phase 2). 
It was somewhat surprising to the inventors that other 
chemicals not strictly considered polymers, such as 
lecithins, when used to make the microcapsules of the 
invention, also laid down a polymer-like skin or film at the 
interfaces of the two phases. Thus, depending on the char- 
ss acteristics of the particular bioactive agent selected for 
encapsulation, the following sterols and phospholipids may 
be substituted for Polymer 1: cholesterol, the plant sterols 
stigmasterol, phytosterol and campesterol, or lecithins such 
as phosphatydyl choline (CENTROLEX-FTM). In any event, 
60 acceptable hydrocarbon-soluble polymers (or non- 
polymeric membrane forming materials which can substi- 
tute for Polymer l) ,  will generally have lower HLB values, 
in the order of less than 1 to about 12. Polymer 1 is insoluble 
or sparingly soluble in water. 
35 
SO 
65 Polymer 2 
Polymer 2 is water soluble and is preferably chosen from 
the following: PEG 400-20000, dextran 4000-20,000, a 
US 6,676,964 B2 
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polysaccharide of mol. wt. ranging from about 4,000-100, occurs between the phases. The two immiscible phases are 
000, polyvinylpyrrolidone (PVP), a polyvinyl alcohols or brought together in such a mechanical manner that the fluid 
another similar polymeric material. Polymer 1 and Polymer shear properties are controlled to low levels from 0 to 100 
2 are selected such that they cannot solubilize each other, dynesicm’, preferably below 50 dynesicm’, and most pref- 
and they do not chemically react to form new and distinct s erably 12 dynesicm’ or below, such that the adsorptive 
adducts. Preferably Polymer 2 is capable of adhering to surface properties at the immiscible interfaces are not sig- 
Polymer 1, however, and in preferred formulations the nificantly altered. Although the exact mechanisms are not 
microcapsule’s final, or “cured,” membrane is actually a fully understood, the inventors believe that the maintenance 
composite of Polymers 1 and 2. In this case, Polymer 2 of certain adsorptive surface properties, such as the surface 
serves to enhance the strength of the outer membrane or i o  tension, Helmholtz charge distribution (electrical double 
skin, which is primarily made up of Polymer 1. It should be layer), and partitioning of the surfactant molecules between 
noted that the inventors have succeeded in making protein- the immiscible phases must remain substantially intact so 
and crystal-filled microcapsules using only Polymer 1 as the that lateral phase separation of phases can occur to form the 
skin-forming material. However, a sturdier membrane is wateriorganic interface. This is believed to be the mecha- 
obtained when the second polymer, Polymer 2, is included. is nism for the formation of multi-lamellar vesicles which are 
Using the same rationale for selection, additional suitable formed in a single step, as discussed in U.S. patent appli- 
polymers could be included in the Phase 1 of Phase 2 cation Ser. No. 081349,169 (now U.S. Pat. No. 5,827,531). 
solutions to form the composite polymeric skin. Although best demonstrated under microgravity conditions, 
Surfactant wherein buoyant convection is absent and diffusion-driven 
A suitable surfactant for dissolving in the aqueous Phase 20 convection predominates, favorable microcapsule forming 
2 solution can be any of the following ionic or non-ionic conditions are also accomplished in unit gravity environ- 
compounds: sorbitan monooleate plus ethylene oxide, ment by balancing the density differences between the two 
dextran, polyethylene glycol (PEG), C,,-C,, fatty acids or liquid phases or by any other mechanical means which 
a quaternary NH, salt. The surfactant chosen will typically prevents excess fluid shear from significantly altering the 
have a higher HLB value, in the range of about 10 to 40. The zs normal adsorptive surface properties which are determined 
surface active agent is selected so that it has an HLB value by the chemical composition of the formulas and the inter- 
sufficiently different (preferably HLB>2 or more units facial phenomena among the solvents, polymers and 
different) from that of either polymer 1 or 2, so that the surfactants, as described above. One way of creating a 
surfactant will lower the interfacial tension just enough to suitable interface is by sliding individually separated com- 
promote film (outer skin) formation by polymer 1 and/or 30 partments containing the two phases into register with one 
polymer 1 plus polymer 2. but does not lower the surface another in a manner that substantially limits shear and 
tension enough to cause complete emulsification of the skin provides gentle mixing, as shown in the schematic illustra- 
polymer(s) in the second solvent. The surfactant itself does tion in FIG. 1A. 
not form a major component of the outer film, or skin, which Interface Formation 
surrounds the microcapsule, encapsulating the drug or other 3s The two liquid phases formulated as described above are 
bioactive agent. placed into separate compartments or spaces which are each 
Salt connected to a central diffusion chamber into which each 
compartment can deliver its resident liquid loading. The 
cetyl trimethylammonium bromide, 2-methyl-2amino- compartments are initially closed to access into the central 
aminomethyl propanol or another similar salt. 40 diffusion chamber so that the first and second liquids are 
Bioactive Substance kept apart from one another and not allowed to interact. The 
The protein or bioactive substance, or agent, is preferably separation of the two liquids is maintained until both liquids 
a protein that can be crystallized, but it may also be another and the device containing them can be placed in an envi- 
bioactive substance or agent that is compatible with the ronment in which convective mixing may be minimized, 
microcapsule-forming materials and is capable of forming a 4s such as in a microgravity environment. FIG. 1 A  is a sche- 
crystal or other highly ordered structure. Some other types matic illustration of one way that a liquid-liquid interface 
of molecules that are suitable for encapsulating are struc- may be achieved, and shows conceptually the structure of 
tures such as a double stranded DNA a-helix, polypeptides, the microcapsules formed. While it is possible to use any 
oligonucleotides, D- or L-stereoisomers, pharmaceutical number of devices to accomplish this separation, a preferred 
compounds, toxic agents, and the like. A protein stabilizing SO apparatus for use in creating the optimal low-shear condi- 
agent may also be included in the Phase 2 solution when the tions favoring spontaneous interfacial coacervation is the 
substance to be microencapsulated is a protein that is easily Materials Dispersion Apparatus (MDA) (manufactured by 
degraded. Some suitable protein stabilizing agents are ben- ITA, Inc., Exton, Pa.), which is described in U.S. patent 
zamidine and 2-MP. application Ser. No. 081349,169 (now U.S. Pat. No. 5 
Optionally, an oil can be added to the Phase 1 solution. ss 827,531). Another suitable apparatus is the Microencapsu- 
For example, in some applications it may be desirable to lation Electrostatic Processing System (MEPS), which is 
include a marker or tracer for tracking the location of the described in a companion U.S. patent application entitled 
microcapsule in the body. A radiocontrast material such as “Microencapsulation and Electrostatic Processing Device” 
iodinated poppy seed oil (IPO) could be incorporated into application Ser. No. 091079,833(NASA No. MSC-22937-1- 
the microcapsule to permit detection by radiographic tech- 60 SB), which application is incorporated in pertinant part 
niques. herein by reference. Any suitable apparatus capable of 
The preceding formulations have been used successfully slowly and gently bringing two immiscible liquid phases of 
by the inventors in both Earth normal and in microgravity differing densities together and permitting spontaneous for- 
environments to form liquid-filled microcapsules. mation of microcapsules may be used however, as long as 
The basic method next creates an interface between the 65 the required low shear conditions (i.e., 0-100 dynesicm’) 
first and second phases. The creation of the interface is are maintained. Shear forces of 35 dynesicm’ and below 
achieved in such a way that minimal shear and mixing have been demonstrated by the inventors during the spon- 
Suitable salts are NaC1, KC1, CaCl,, quaternary NH, salts, 
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taneous formation of representative microcapsules at the 
interface of the two phases under conditions of Earth normal 
gravity and in microgravity, as illustrated in FIGS. 3A and 
3B, for example. 
Calculations were made for shear forces occurring in 
various types of apparatus which have been used to suc- 
cessfully make the multi-layered microcapsules. Original 
calculations for shear stress in cell syringes were extended 
to calculations for Liquid Mixing Apparatus (LMAs) made i o  
by ITA, Inc. in Exton, Pa. Microcapsules were formed using 
-continued 
Icm cm 
5 900 0.090 
1000 0.100 
then T= 
several representative formulations taken from Table 2, for 
the alcoholic (Phase 1) and aqueous (Phase 2) phases. 
(dynesicm’) 
35.6 
27.57 
19.50 
13.79 
11.26 
8.72 
7.96 
6.50 
6.17 
In order to form microcapsules, the interfacial surface 15 
tension must not be overcome by shear stresses, at least until 
the “outer skin” has formed and stabilized, after which the 
microcapsules can withstand even higher shear stress. The 
toughened outer skin can be observed by observing a sample 
of the microcapsule suspension under the microscope. The 20 
microcapsules tumble in gentle fluid flow rather than disin- 
tegrate. A basic assumption is that the microcapsules do not Thus, the fluid shear stress at 30 microns is 35.6 dynes/ 
form efficiently in the high shear stress fields within a cm’ and is reduced to 11 dynes per cm’ at 300 microns from 
distance equal to three (3) diameters from the container the interface. In each instance, microcapsules were observed 
walls or immiscible interface, The following ca~cu~ations 25 to form. Experiments performed in the inventors’ laboratory 
indicate that most 10 micron diameter m~crocapsu~es would indicate that the microcapsules of most interest (i.e. >10 
be formed in the boundary layer from 3o microns to o,2 cm microns in diameter) do not form within 3 4  diameters (30-50 microns) from the interface. The microcapsules of the immiscible interface. described in these Examples were formed using the basic 
for 30 procedure described above, in shear fields calculated to be 
forming representative microcapsules including the follow- approximate~y 35 dynes/cm2, The largest microcapsu~es 
ing assumptions: the two fluids are incompressible, immis- (i,e,, ranging from about 50 microns to 2 mm), which are 
cible and one acts similar to a solid wall; the viscosity of especially preferred for crystal x-ray diffraction studies, are 
Phase 1 (Med-10) at 20” C. @’) is 0.01716 gicm-sec; the probably best formed in the more quiescent region of the 
viscosity of Phase 2 (aqueous Cis-Platinum-11) @’) is 35 boundary layer which is about 100 microns or farther from 
0,0101 gicm-sec; the average dynamic viscosity (p’) is the container wall. This corresponds to a shear stress field of 
0.01363; the density of Phase 1 (p’) is 0.802; the density of 19 dynesicm’ or less. When microcapsules of about 20 
Phase 11 (p’) is 1.009; the effective kinematic viscosity (VI )  microns in size are desired, such as for in vivo use as drug 
is 0,015703, where (V’)=(@’/p’)+@’/p’)/2; the maximum carriers, relatively higher shear conditions are permissible. 
fluid velocity along the container wall or immiscible 40 Minimal shear conditions are critical in gravity dependent 
interface=\/’,,, i.e., 14.29 cmisec. conditions (i.e., 21 g). In this case, the optimum microcap- 
sules are formed when the fluid shear between the immis- 
cible Phase 1 and Phase 2 liquids is restricted to 1&100 
dynesicm’. Under microgravity conditions (i.e., e1 g) the 
45 fluid shear forces can be better controlled in the range of 
about 2-30 dynesicm’. 
In the next step of the basic method, conditions are 
established for substantially limiting all mixing between the 
interfaced liquid phases. Preferably, the two phases are 
SO allowed to interact at their interface without agitation, 
stirring, shearing or like force for a period of about 1-10 
minutes. Preferably the temperature is maintained within 
about 21” C. of the maximum solubility temperature of the 
polymer, but below the denaturation temperature of the 
ss protein or other bioactive substance. For representative 
proteins and drugs demonstrated in these examples, tem- 
peratures up to 43” C. are maintained. It is preferred to limit 
even those quiescent forces such as gravity-controlled 
sedimenting, shifting, drift and the like. Thus, it is low fluid 
60 shear, chiefly diffusion-driven convection, that is used to 
30 0.003 spontaneously form microcapsules, as the chemical formu- 
so 0.00s lations of the different phases assist in lowering the surface 
100 0.010 free energy across the interface. It is also at this time that 
formation of the polymeric outer coating is initiated. The 
500 65 inventors’ recent investigations indicate that, in either unit 
600 0.060 gravity or microgravity conditions, it is advantageous, 
however, that the two phases be allowed to interact at their 
Shear-Laminar 
Shear Stress (T) is 
(0 3 2 )  (PI ( Vm, 1 E 
6 T =  
where p = ~ (P’ + 2) 
and T =  ~ 1.94981 2 
2 
6 
where x=distance (cm) from wall or interface 
Therefore, when x= 
Icm cm 
0.020 200 
300 0.030 
0.050 
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interface with a small amount of fluid shear force applied 
(approximately 2-40 dynesicm’), in order to increase the 
yield of microcapsules. The maximum practical shear force 
is a function of the kinematic viscosity of each fluid at the 
interface. The shear force should not produce a Reynolds 
number greater than 300. Uniformity and sphericity is a 
common characteristic of the microcapsules of the 
invention, regardless of the gravity environment in which 
they are produced. 
As shown in FIG. lA,  the microcapsules 10  have an 
aqueous solution 30 of a bioactive substance 50 in the 
interior compartment 12 and have polymeric outer coatings 
or skins. Polymer 1 and Polymer 2 together form a rugged 
composite polymer membrane or shell 65, after curing. 
Polymer 1 primarily makes up the outermost part 60. FIG. 
1B illustrates conceptually how the two polymers are 
thought to be distributed when the microcapsule initially 
forms. Polymer 1 (60) and Polymer 2 (70) are substantially 
distinct layers, at least initially, with Polymer 2 (70) adher- 
ing to Polymer 1 from the inside of the microcapsule and 
providing enhancement of the outermost membrane formed 
by Polymer 1. 
In the present studies, large, uniformly spherical micro- 
capsules have been prepared without using conditions of 
microgravity for limiting mixing between the phases. Limi- 
tation of interactions between the phases is best promoted by 
substantially balancing the specific gravity between the 
phases. By varying the density of the polymer solutions, 
convection can be reduced, as further described below. In 
either microgravity or unit gravity, using the procedures and 
rationale described herein, mixing between the two phases is 
controlled such that it is chiefly the result of diffusion-driven 
convection and not a function of density driven bouyancy, 
and fluid shear is limited to about 2-100 dynesicm’ and 
interfacial mixing is counteracted by the surface free energy 
of the respective phases. 
Curing of the Membrane 
Studies on the Space Shuttle permitted 10 minute disper- 
sion times followed by curing of the outer skin (exemplified 
by a polyglyceride) for eight days under microgravity con- 
ditions. The microcapsules formed in the microgravity envi- 
ronment are generally obtained in better yield and of larger 
average size than at Earth normal gravity, as shown in FIGS. 
SA and SB. At 1 g, a wide range of sizes generally smaller 
microcapsules is typically obtained. The frequency vs. size 
data shown in FIGS. SA and SB were obtained for repre- 
sentative microcapsules containing the drug photofrin. 
These microcapsules contained photofrin in the form of a 
saturated or nearly-saturated solution variously with or 
without photofrin crystals. The inventors have observed that 
the nature of the active material that is encapsulated can 
affect the resulting size range of the microcapsules. 
The distribution of microcapsules obtained by a repre- 
sentative procedure ranges from uniform spheres of about 1 
to 300 microns in diameter. By varying the formulations so 
as to reduce the density differential between the aqueous and 
organic phases, even larger microcapsures are formed, up to 
about 2 mm, as previously discussed. The average size of the 
microcapsules formed in one representative procedure, 
shown in FIG. SB was about 35 microns. 
The ground-based production of microcapsules is able to 
replicate the size range (roughly 5-250 microns in a repre- 
sentative study), but the average size microcapsule is typi- 
cally about 10-40 microns in diameter, as shown in FIG. SA. 
At least a partial reason for this wider size distribution at 
Earth-normal gravity is the apparent inability at 1 g to avoid 
certain sedimentation phenomena alone and sedimentation 
18 
effects combined with weight-related contact of sedimented 
microcapsules. The gravity-dependent deformations of the 
spherical microcapsules as they form give rise to areas of 
thinner polymer deposition. Thus, the flexible microcapsules 
s formed under microgravity conditions tend to have more 
uniform size distributions than those formed in Earth-normal 
gravity, are more rugged, and have a higher average diam- 
eter than ground-made microcapsules, largely due to the 
absence of thermal convection, buoyancy forces, and insta- 
i o  bilities that occur at the immiscible interfaces. 
These factors necessitate some additional manipulation 
under Earth-normal environments that is not required in the 
microenvironment, namely, size separation of the resulting 
microcapsules in order to obtain fractions of more uniform 
is size microcapsules. Therefore, at 1 g the durability of the 
outer coating of the microcapsules of the present invention 
becomes even more important. The curing step significantly 
enhances the ruggedness of the Earth-normal microcapsules. 
An outstanding characteristic of these microcapsules is their 
20 sturdiness, as demonstrated by their ability to withstand size 
segregation by filtration or sieving. 
The microcapsules of the present invention are equal or 
superior in size and function to microcapsules prepared by 
conventional methods. The inventors believe that there are 
zs no previously known methods of making microcapsules 
designed for growing a protein crystal inside the microcap- 
sule. Due to their novel methods of making, the microcap- 
sules prepared as described herein may have other signifi- 
cant features or advantages over known microcapsules that 
30 cannot be fully identified or appreciated at the present time. 
EXAMPLE 2 
Protein Crystallization within a Microcapsule 
Referring now to FIGS. 1 A  and 2, microcapsules con- 
taining the representative protein lysozyme were prepared 
essentially according to the general method described in 
Example 1. The Phase 2 formulation contained 7% wiv 
lysozyme from hen egg, and 0.01M sodium acetate, pH 4.0, 
In FIG. lA,  the production of microcapsules is schemati- 
cally shown. Microcapsule 10 contains the Phase 2 solution 
30, containing lysozyme molecules 50 in the interior cavity 
or compartment 12. The microcapsule initially has an outer 
45 polymeric membrane 65, made up primarily of Polymer 1, 
and an adherant polymeric layer 70 (FIG. 7B), which is 
primarily Polymer 2. After letting the microcapsules rest 
quiescently in the Phase 1 and Phase 2 solutions for up to 
about 1 hr., the outer skin 65 had fully formed and stabilized 
50 (cured) and the microcapsules are then able to withstand 
shear stresses equivalent to the fluid flow in a human artery, 
or a Reynolds number of up to about 300. 
The microcapsule skin is preferably less than 1 micron 
thick when crystal growth within the microcapsule is of 
ss primary interest, as in the present example. When the 
primary goal is to place a protective, less permeable coating 
around a preformed crystal or to provide a carrier for a 
concentrated protein solution, however, a thicker polymeric 
skin of about 2-3 microns is preferred. The thickness of the 
60 skin may be increased, and the permeability decreased, by 
suspending the microcapsules in the Phase 1 solution, or in 
a similar alcoholicipolymer 1 solution, to apply an addi- 
tional layer of polymer over the outer skin. Repeated appli- 
cations will build up the skin to the preferred degree of 
65 thickness. As part of this skin thickening step, a “handle” 
such as an immunoglobulin-bound polymer, may be 
included, if desired. 
35 
4o dissolved in water. 
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Optionally, a fractionating step such as filtration or tioned between the mother liquor and the dewatering (high 
sieving, may be performed to isolate a fraction of micro- osmotic pressure) salt solution. The present method uses 
capsules within a specified size range. The fluid surrounding spherical microcapsules wherein the entire outer membrane 
the microcapsules was then exchanged for a dewatering fluid surface is available for osmotic dewatering. The spherical 
120 having a higher osmotic pressure such that water 5 membrane also optimizes conditions for infiltration by 
molecules diffused out of the semi-permeable outer mem- hydrogen or hydroxyl ions, thereby changing the pH within 
brane. The dewatering fluid contained 25% (wiv) NaCl the microcapsule to favor or enhance protein saturation and 
dissolved in deionized water. Alternatively, another similar subsequent crystal growth. The increased surface area of the 
salt could be used, at a concentration that provides an spherical microcapsule allows for more rapid change in 
osmotic value at least 10% greater than that of the mother conditions throughout the sphere of mother liquor, hence 
liquor. Similarly, a solution of 18% (w/v) higher molecular faster controlled changes all around the crystals which 
weight material such as polyethylene glycol (PEG) 8000 enhances the formation Of more Ordered and Perfectly 
dissolved in deionized water may also be used for dewater- formed crysta1s. 
ing the microcapsules, or another high molecular weight By varying the choice and relative amounts of the Phase 
1 and Phase 2 components and/or by fractionating the PEG (of about 4-20 kDa) may be substituted. 
Referring still to FIGS, 1~ and 2, the higher osmotic microcapsules, one can easily optimize the size range of the 
pressure of the dewatering fluid 120 causes water molecules microcapsules needed for a particular Protein, drug 
to diffuse out of the semi-permeable outer membrane 65 of compound, or other bioactive agent. For some uses, such as 
the microcapsules, thereby dehydrating the mother liquor 35 in Vivo drug carriers, microcapsules of 5-25 microns will be 
to nucleate lysozyme crystals 55. The dewatering fluid 2o preferred. For other uses, uniform spherical microcapsules 
sustains osmotic conditions that favor the growth of the of greater than 25 microns are needed; and in still other 
lysozyme crystals within the microcapsules. The dewatering such as crystallograPhY very 
process is continued until extensive dewatering ofthe micro- large 5 0 - 2 0  micron crystals Protected by an inert mem- 
capsule is achieved, after which only a small amount of the brane ‘Overing are wanted. 
mother liquor 35 remains and the flexible skin of the 25 FIG. 3 shows another representative protein crystal, the 
microcapsule substantially conformed to the shape of the PhYtohemagglutinin CO~~anavalin A, which was encapsu- 
large crystal. As can be seen in FIG. 2, the lysozyme crystal lated and crystallized essentially as described for lysozyme. 
essentially fills the interior of the microcapsule. A lysozyme The aqueous Phase contained 40 mdml  CODA, 4.25 d l  
crystal produced in this way is of high quality, due to its sodium nitrate, 47.4 mgil manganese chloride, 27 mgil 
large size and internal structural order. The protective skin 3o calcium chloride, and 43.7 mgfl TRIS acetate buffer, PH 6.5, 
crystal to grow unperturbed by contact with a container wall C o ~ c r Y s t a l s  and mother liquor, as formed at Earth normal 
or with other crystals. After completion of crystal growth, gravity. FIG. 3B shows the Same type of microcaPsUles 
the tough, somewhat elastic, outer skin continues to protect formed under conditions of microgravity on board the Space 
fragile crystalline structures from breakage, and deterred 35 Shuttle. 
penetration by the sharp crystal edges. Preferably the outer The above-described procedure can be readily modified, 
skin is about one micron or less in thickness, for obtaining if desired, by the encapsulation of a first phase comprised of 
optimum dewatering rates. an aqueous, near-saturated solution of protein, or other 
Microcapsules containing the lysozyme crystals are con- bioactive substance, and a carefully selected hydrophobic 
veniently harvested either by 1) suspending in a liquid 4o surfactant which is capable of permeating through the mem- 
carrier phase with a micropipette or 2) capturing with a brane such that the entrapped hydrophilic protein molecules 
hydrophobic fiber loop, preferably one having a surface become super-saturated. The super-saturated condition can 
charge more or less opposite that of the microcapsule. The be controlled such that nucleation of one or a few, well- 
microcapsules are then ready for analysis by polarized light ordered crystals occurs as the surfactant is transported 
microscope to determine the size and shape of the crystal(s) 45 through the semi-permeable ‘‘Outer m d ~ a n e ”  of the micro- 
contained inside or mounting in an x-ray capillary tube, as capsules. 
illustrated in FIG. 1A. Because the crystal is bathed in Another way to enhance protein crystal formation within 
mother liquor within the microcapsule, drying out of the the microcapsules is to add a salt to the surrounding fluid As 
crystal in the x-ray capillary tube is retarded or eliminated. with conventional salting out procedures, any suitable non- 
The polymeric membrane components selected for formu- 50 denaturing salt such as (NH4),S04 or NaCl can be used, 
lating the microcapsules are selected to be transparent to provided that it can diffuse through the polymeric skin to 
x-rays and are preferably non-x-ray diffracting. FIG. 1C cause the gradual “salting out” of the protein or it causes 
shows an alternative embodiment of the microcapsules of dewatering through the membrane. 
the invention as used for x-ray crystallography in a proce- In an alternative dewatering process, the basic method 
dure that omits use of a quartz capillary tube. Use of the 55 may be modified by encapsulating an aqueous near-saturated 
microcapsules for x-ray diffraction studies is discussed in solution of protein in a semi-permeable membrane and then 
more detail in Example 4, below. suspending the microcapsules in a carefully chosen dewa- 
This method provides distinct advantages over prior art tering fluid which, upon being subjected to a controlled 
methods of growing protein crystals by providing a closed electrostatic field, regulates the dewatering rate from the 
environment which favors crystal growth under prescribed 60 microcapsules by controlling the local salt concentrations on 
conditions of controlled dewatering. It avoids the problem of either side of the semi-permeable membrane. By controlling 
having a large crystal fall out of a hanging drop, as fre- the concentration of protein and charged precipitant mol- 
quently encountered in conventional vapor diffusion meth- ecules at or near the surface of the growing protein crystal, 
ods. It also avoids having the crystal touch a container wall. the quality and size of the resulting crystal structure can be 
In the past, typical methods employing osmotic dewatering 65 further optimized. 
for growing protein crystals have relied on use of small A suitable method and an apparatus for applying an 
chambers having a planar reverse osmosis membrane posi- electrostatic field to the microcapsule are disclosed in the 
15 
that surrounds the mother liquor and the crystal permits the dissolved in water. FIG. ~ A S ~ O W S  microcapsules containing 
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inventors’ related applications cross-referenced above. It is EXAMPLE 4 
believed that no crystal growth-enhancing method in use Crystal Preparation for X-ray Diffraction Analysis today employs electrostatic fields to manipulate the local 
concentration of protein molecules or charged precipitant MicrocaPsules containing Protein crystals measuring 
molecules near the surface of the crystal as it is growing. s about 5 C k 2 0  microns on a side, are Prepared as described 
Although there are numerous ways of establishing an elec- in Examples 1-3. The Polymer 1 and Polymer 2 materials 
trostatic field, one suitable apparatus is described in the chosen for use are Preferably transparent to x-ray 
inventors’ related application (cross-referenced above) wavelengths, SO as not to cause interfering diffraction pat- 
describing the ~i~~~~~~~~~~ and Electrostatic processing terns. The particular formulations used are optimized for 
System (MEPS) for controlling precipitant and protein con- 10 formation Of Very large miCr0CapSUkS Containing a saturated 
centrations inside the protective environment of the micro- or near-saturated protein solution by generating the micro- 
capsules. The disclosure of that application is incorporated capsules under conditions of very low shear field. Micro- 
herein by reference, to the extent that it provides details capsules containing crystals of the desired size are individu- 
supplementary to those set forth herein. ally selected and carefully transferred into an x-ray capillary 
ne inventors have also made the surprising discovery 1~ tube or other mount so the crystal can be orientated in a high 
that addition of energy in the form of uv light to the contents energy x-ray beam for diffraction studies, in accordance with 
a change  in  chemica l  equi l ibr ium, producing  ciently protected by the skin of the microcapsule such that 
tal growth. Ongoing investigations by the inventors are 20 cessfully into the tubes. 
aimed at clarifying the mechanism by which this occurs. Representative microcapsules containing large lysozyme 
The inventors believe that there are no previously known crysta1s were 
methods of making microcapsules designed for growing a in a liquid carrier phase with a micropipette or 2) capturing 
with a hydrophobic fiber loop. The microcapsules were then 
2s ready for analysis by polarized light microscope to deter- 
EXAMPLE 3 mine the size and shape of the crystal(s) contained inside or 
mounting in an x-ray capillary tube, as illustrated in FIG. Encapsulation of a Preformed Protein Crystal and 1A. Because the crystal is bathed in mother liquor within the Continued Crystal Growth microcapsule, drying out of the crystal in the x-ray capillary 
fication showing a large lysozyme crystal that was encap- As illustrated in FIG. l C ,  alternatively, a microcapsule 
Sulated as a large Preexisting crystal suspended in the Phase containing a large, high quality crystal is also suitable for 
2 solution, Prepared as described in Example 2 and saturated advantageous use in an x-ray crystallography procedure that 
Or nearly saturated with dissolved lysozyme. The microcap- avoids the problem of manipulating a specimen into a quartz 
was subsequently submerged in water for 12 hours Prior 3s x-ray capillary tube. Such a method generally includes 
to being Photographed. It can be readily Seen that the large “lassoing” a crystal specimen, together with a drop of liquid, 
crystal substantially fills the interior cavity and the skin in a fiber loop, While the crystal is heid in suspension within 
around the microcapsule conforms to the shape of the the loop, supported by the surface tension of the surrounding 
crystal, with only a thin layer of mother liquor remaining liquid, the loop is placed into liquid propane to freeze the 
between the crystal faces and the skin. The Permeability of 40 crystal specimen. The loop is then manipulated by its handle 
the membrane was such that the lysozyme crystal had and the handle is mounted on the goniometer head of the 
redissolved only minimally Over the 12 hour water exposure x-ray device. The frozen crystal, together with the associated 
period. This establishes that the speed of water diffusion mother liquor, is thereby situated in a continuous stream of 
through the membrane can be limited to a very Slow rate, for nitrogen gas so that the crystal remains frozen while being 
optimizing crystallization conditions. If desired, the micro- 45 manipulated under the x-ray beam, Referring to FIG, IC, a 
capsule can be submerged in the alcohol/PolYmer 1 solution microcapsule 10 containing a large crystal 55 of any desired 
to receive an additional coating of Polymer. This would substance, especially a protein or drug crystal, prepared as 
Provide a thicker, less Permeable, more rugged Polymer coat described herein, is captured, supported and manipulated by 
for the microcapsule, on the order of about 3-57 microns. a fiber loop 130 without relying on liquid surface tension to 
This demonstrates that it is possible to form sturdy so hold the specimen in place. Not only does the sturdy, x-ray 
membranes around existing crystals of a representative transparent membrane 65 of the microcapsule protect the 
protein and thereby provide protection for even the most fragile crystal structure while the specimen is being “teased” 
fragile crystals. The encapsulated crystal avoids the problem into the fiber loop, the polymeric skin can readily be 
of redissolution of thin crystalline structures, typically adjusted to have an electrostatic charge on its surface. By 
encountered with most conventional crystal growing and ss advantageously choosing the fiber loop material and/or by 
handling procedures. applying an opposite electrostatic charge to the fiber loop, 
The microcapsules formed by the processes described in the microencapsulated crystal specimen is held in place in 
Examples 1-3 have the unique characteristic that they can be the loop and supported by electrostatic attraction. For 
exposed to high osmotic solutions of salts, polymers, etc. example, the microcapsule membrane may have a negative 
which will cause dewatering of the mother liquor within the 60 charge and the polymer fiber loop may be positively 
microcapsules, thereby maintaining a preexisting crystalline charged. Some suitable fiber materials are nylon, cellulose 
structure and even allowing continued crystal growth within and polyethylene terphthalate. The microencapsulated crys- 
the protective confines of the outer membrane. The present tal specimen is then frozen and situated under the x-ray 
example also demonstrates that when the microcapsule has beam in the same manner as other crystals via handle 140 
received a thicker polymer coating the microcapsule offers 65 attached to the goniometer head 150. The new microcap- 
even more protection to the crystal, while reducing water sules containing large crystal specimens of 50-300 microns, 
permeability and redissolution of the crystal. and even up to about 2 mm in size, can be supported 
of the protein-containing microspheres also appears to cause 
supersaturation, crystal nucleation and acceleration of crys- even sharp-edged crysta1s can be sue- 
methods. The crysta1s are suffi- 
harvested either by 1> 
protein crystal in the interior cavity of the microcapsu~e, 
FIG. 5 is a photomicrograph taken at about lOOx magni- 30 tube is retarded or eliminated. 
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electrostatically and manipulated with the fiber loop for 
examination by x-ray crystallography. 
EXAMPLE 5 
Protein Crystal Growth between Two Solvent 
Phases within a Microcapsule 
FIG. 7 is a conceptual drawing of a layered microcapsule 
made essentially as described in Examples 1-3. An aqueous 
saturated or nearly saturated solution of protein, or other 
bioactive agent (30) is encapsulated, between a non- 
aqueous, hydrocarbon phase (20) which is only partially 
miscible with the aqueous solution (30) and a third, solid 
phase composed of a semi-permeable polymer that forms the 
outer membrane (65) and which is in contact with a high 
osmotic concentration aqueous solution of salts or polymers 
(120). Dewatering from the protein solution (30) occurs by 
migration of water into the hydrocarbon liquid phase (20) or 
by transport out of through the semi-permeable membrane 
into the high osmotic solution (120). The particular hydro- 
carbon components selected for the core liquid, or hydro- 
carbon phase (20) are chosen based on their characteristics 
of being slightly miscible with water to the desired degree. 
This embodiment of microcapsules may be advantageous for 
more rapidly dewatering certain proteins or other bioactive 
agents. 
EXAMPLE 6 
Encapsulation and Crystallization of Cis-Platin 
Referring now to FIGS. 6A and 6B, a 2% (wiv) solution 
of the representative pharmaceutical drug cis-platinum was 
microencapsulated essentially as described in Example 1, 
however 5% (wiv) iodinated poppy seed oil (IPO) was also 
included in the Phase 1 solution. The formulation is 
described in Table 3. 
TABLE 3 
Phase 1 
(“MED lo”) Phase 2 
88.0% isopropyl alcohol 0.2% Cis-platinum 
2.5% n-hexanol 1% PEG-4000 
2.5% n-heptanol 
5.0% IPO 
2.0% H,O 0.8% NaCl 
5% wlw Glycerol Monosterin 
5% Dextran-40 (MW = 40,000) 
1% Sorbitan Monooleate-20 moles 
ethylene oxide 
Balance - sterile water for injection 
(GMS) 
This concentration of cis-platinum was sufficient to allow 
nascent crystal formation within the microcapsule. In this 
case, crystal formation occurred at or near the time of 
formation of the microcapsule containing the dissolved 
pharmaceutical material. It can readily be appreciated that 
the components of the aqueous solvent system used to 
dissolve an aqueous-soluble pharmaceutical agent may be 
advantageously selected, and their concentrations adjusted, 
to permit water molecules to migrate away from the drug- 
containing layer into the alcoholic mixture. The process of 
crystal formation is likely to be promoted in this manner 
after formation of the microcapsule. The results obtained in 
this investigation for cis-platinum is considered to be rep- 
resentative of other bioactive agents which can be similarly 
encapsulated. 
Using the above-described methods, an aqueous solution 
of a drug or other bioactive agent which is non-saturated 
may be brought to super-saturation and crystal nucleation 
after encapsulation, via controlled transport of water out of 
the microcapsule’s interior compartment, as described 
above. In this way it is possible to enhance the crystalliza- 
5 tion process after the microcapsule is formed. As shown in 
FIGS. 2-4, the crystal thus formed may take up most of the 
internal capacity of the microcapsule, i.e. about 65-90% of 
the internal volume. 
Another representative drug, the antibiotic amoxicillin, 
was encapsulated essentially as described above, and the 
resulting microcapsule containing amoxicillin crystals and 
mother liquor is shown in FIG. 4. 
If desired, co-encapsulation of a radio-contrast medium, 
as shown in FIG. 6B, enables oncologists to monitor the 
delivery of anti-tumor microcapsules to target tumors using 
computerized tomography and radiography that track the 
distribution of microcapsules after release from the intra- 
arterial catheter. Such microcapsules will have important 
applications in chemotherapy of certain liver, kidney, brain 
and other tumors. 
The diameters of microcapsules possible to attain using 
the methods of the invention are also of particular usefulness 
in medical applications. Thus, whereas prior art methods 
have been able to routinely produce microspheres of about 
1-10 micron average sizes, the present methods provide 
25 similarly-sized microcapsules of 1-20 micron diameters for 
intravenous administration. Also provided are 50-300 
micron sized microcapsules particularly useful in interarte- 
rial chemoembolization of tumors, and microcapsules in the 
range of 300 micron and greater diameters useful in inter- 
30 peritoneal administered drugs. The membrane or skin 
around the outer surface of the microcapsule avoids being 
readily detected and largely eliminated by the reticuloen- 
dothelial system (RES). The outer skin protects the micro- 
capsules against shear forces encountered during manufac- 
35 turing processes and during transport within the vascular 
system enroute to the target tissues. The hydrophobic outer 
membrane can also be modified, by selection of advanta- 
geous polymeric and/or non-polymeric components, so as to 
retard oxygen transport and thereby reduce oxidative deg- 
40 radation of the entrapped drug. This would likely improve 
the shelf-life of parenteral suspensions. The flexible, 
deformable outer skin on the microcapsules of the invention 
provides increased packing densities within vascular beds. 
This results in microcapsules superior to prior art solid 
45 microspheres (e.g. gelatin, albumin or starch) commonly 
used for chemoembolization therapy against tumors. It is 
expected that the new microcapsules, carrying more con- 
centrated amounts of drugs which are already known to be 
therapeutically effective, will be even more effective as 
50 substitutes for existing liposome encapsulated drugs. The 
thin, semi-permeable membrane of some embodiments of 
the new microcapsules permits controlled release of the 
encapsulated drug at the desired site of action. Since the 
concentration of drug in a microcapsule and its release rate 
5s are easily determined, the correct microcapsule dosage for a 
particular drug can be calculated from the customary dos- 
ages for that drug. 
As another option, the polymeric skin may be made 
initially insoluble in Phase 2 but slowly solubilizable in 
60 physiological body fluids (e.g., blood, serum, plasma, extra- 
cellular fluid, saliva, mucus). Alternatively, sustained or 
controlled release at a therapeutic target site may be obtained 
by modifying the above-described method to provide a 
somewhat thinner, drug-semi-permeable membrane on the 
65 microcapsule. Upon injecting into a person in need of the 
drug, the microcapsules serve to protect tissues, arterioles 
and veins from the sharp edges of the drug crystals. 
2o 
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forming a microcapsule containing a saturated or near 
saturated aqueous solution of said protein surrounded 
by a semi-permeable polymeric membrane; 
exposing said microcapsule to a dewatering solution 
having a higher osmotic pressure than said encapsu- 
lated protein solution whereby water is osmotically 
removed from said encapsulated protein solution; 
controlling the concentration of a dewatering agent in said 
dewatering solution such that gradual, ordered crystal- 
lization of said protein occurs within said microcap- 
sule; 
growing said crystal to at least about 50-300 microns; 
harvesting the resulting crystal-containing microcapsule; 
selecting a microcapsule containing a crystal of sufficient 
size and crystalline quality for obtaining an x-ray 
diffraction pattern. 
2. An improved method of determining the three- 
25 
While the preferred embodiment of the invention has been 
shown and described, modifications thereof can be made by 
one skilled in the art without departing from the spirit and 
teachings of the invention. For example, a saturated non- 
aqueous solution of a drug could also be similarly encap- s 
sulated and then exposed to conditions which would remove 
solvent through the outer membrane, producing a similar 
supersaturated condition, crystal nucleation and/or accelera- 
tion of the drug crystal growth, within a microcapsule. The 
embodiments described herein are exemplary only, and are i o  
not limiting. Many variations and modifications of the 
invention disclosed herein are possible and are within the 
scope of the invention. Accordingly, the scope of protection 
is not limited by the description set out above, but is only 
limited by the claims which follow, that scope including all is 
equivalents of the subject matter of the claims. 
- 
dimensional structure of a predetermined protein molecule 
by x-ray crystallography including isolating a crystal speci- 
Liposomes: An Improved Sustained Release System for 2o men of said protein in a fiber loop, freezing said crystal 
1-b-D-Arabinofuranosylcytosine,” Cancer Res.  specimen, mounting said crystal specimen and fiber loop on 
5212431-39, 1992. a goniometer head such that said crystal is positioned in a 
Barenolz, Y. and Haran, G., “Method of Amphiphatic Drug continuous cold N, stream loop and kept frozen, and rotating 
Loading in Liposomes by pH Gradient,” U.S. Pat. No. said goniometer in an x-ray beam, wherein the improvement 
5,192,549, issued Mar. 9, 1993. 2s comprises substituting for said crystal specimen a microen- 
Carter, Daniel C., “Apparatus for Mixing Solutions in Low capsulated crystal comprising a protective outer membrane 
Gravity Environments,” U.S. Pat. No. 4,909,933, issued surrounding an interior cavity, said interior cavity containing 
Mar. 20, 1990. a saturated or nearly saturated solution of a protein and 
Carter, Daniel C., “Protein Crystal Growth Tray Assay,” containing a crystal of said protein substantially filling said 
U.S. Pat. No. 5,130,105, issued Jul. 14, 1992. 30 interior cavity, said membrane being transparent to the x-ray 
Martin, et al. “Microreservoir Liposome Composition and beam. 
Method,” U.S. Pat. No. 5,225,212, issued Jul. 6, 1993. 3. The method of claim 2 wherein said membrane com- 
Todd, P., Sidkar, S. K., Walker, C. and Korszun, Z. R., prises an electrostatic charge such that said microencapsu- 
“Application of Osmotic Dewatering to the Controlled lated crystal is electrostatically attracted to said loop, said 
Crystallization of Biological Macromolecules and 3s electrostatic attraction being sufficient to support said 
Organic Compounds,” J.  Crystal Growth 110: 283-292 microencapsulated crystal inside said loop. 
(1990). 4. The method of claim 2 wherein a drop of liquid is 
Willoughby et al., “Neutral Glycolipid as an Adsorbent for adhered to the outer membrane of said microencapsulated 
Enteric Viral Pathogens,” U.S. Pat. No. 5,192,551, issued crystal. 
Mar. 9, 1993. 5 .  The method of claim 2 wherein the outer membrane of 
Woodle, et al. “Liposomes with Enhanced Circulation said microcapsule is negatively charged and said loop com- 
Time,” U.S. Pat. No. 5,013,556, issued May 7, 1991. prises a fiber having a positive electrostatic charge. 
What is claimed is: 6. The method of claim 2, wherein said fiber is nylon, 
1. An improved method of determining the three- cellulose or polyethylene terphthlate. 
7. The method of claim 2, wherein said crystal of said 
protein is a highly ordered structure. 
8. The method of claim 2, wherein said fiber has a surface 
charge opposite that of said microcapsule. 
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dimensional structure of a predetermined protein molecule 4s 
by x-ray crystallography including mounting a crystal in an 
x-ray capillary tube and subjecting said crystal to a high 
energy x-ray crystallographic procedure to obtain a charac- 
teristic x-ray diffraction pattern of said protein crystal, 
wherein the improvement comprises: * * * * *  
